media – Page 2 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Have small molecule weight loss drugs reached their limit?

GLP-1 receptor agonists have garnered widespread attention due to their significant weight loss and diabetes treatment effects. However, despite the remarkable success of existing GLP-1 drugs, many pharmaceutical companies, including Novo Nordisk and Eli Lilly, already established leaders in the weight loss drug market, continue to seek breakthroughs with new drugs and develop convenient and effective treatment options. After the successful Zepbound, which brought endless wealth, Eli Lilly has set its sights on the small molecule asset orforglipron as its next breakthrough, hoping to provide an oral alternative to treat obesity and diabetes. All-round emergency Although orforglipron showed promising results in early clinical trials, especially achieving 15% weight loss in the short term, this effect dropped significantly after entering late-stage trials, to only 11.2%. In comparison, existing injectable GLP-1 drugs (such as Wegovy and Zepbound) demonstrate weight loss effects ranging from 15% to 21%, respectively. This significant disparity presents orforglipron ...
- Source: drugdu
- 33
- August 19, 2025
FDA Approves Tonix Pharmaceuticals’ Tonmya for Fibromyalgia

The FDA has approved Tonix Pharmaceuticals’ Tonmya (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, marking the first new therapy approved for this condition in over 15 years. The approval was based on results from the Phase III RELIEF (NCT04172831) and RESILIENT (NCT05273749) trials, which demonstrated that Tonmya significantly reduced daily pain scores compared to placebo at week 14.1 What makes Tonmya a Breakthrough Option for Fibromyalgia Patients? “The FDA approval of Tonmya as a first-line treatment for fibromyalgia represents a landmark advancement for the millions of people in the US suffering from the debilitating pain this condition causes,” said Seth Lederman, MD, CEO, Tonix Pharmaceuticals, in a press release. “At Tonix, we recognized the transformative potential of pursuing a new approach with Tonmya for fibromyalgia, a chronic overlapping pain condition (COPC), that has gone without innovation for many years. We are hopeful that effectively treating pain ...
- Source: drugdu
- 41
- August 19, 2025
Automatic Health Stations Easy Way To Check For Heart Health Risks

By Dennis Thompson HealthDay ReporterMONDAY, Aug. 18, 2025 (HealthDay News) — Everyone’s seen the automatic blood pressure reader wedged unobtrusively into a corner of their local pharmacy. These sit-down machines can pay huge dividends when it comes to helping people learn their heart health risks, a new study says. Setting up these health stations at community pharmacies – and one international sporting event – led to nearly 7 in 10 young adults learning they had one or more uncontrolled risk factors for heart disease, researchers reported Aug. 15 in the Journal of the American College of Cardiology. “Heart health checks in the community can identify risk factors for future heart disease that can be managed by lifestyle changes or early preventive medications and save lives down the road,” said senior researcher Stephen Nicholls, director of the Victorian Heart Institute at Monash University in Victoria, Australia. “We saw in this study ...
- Source: drugdu
- 35
- August 19, 2025
Pioneering Helicobacter pylori new drug faces commercialization challenge

Recently, Dannuo Pharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as Dannuo Pharmaceutical) submitted a prospectus to the Hong Kong Stock Exchange, intending to list on the main board, which immediately attracted high attention from the capital market. Dano Pharmaceuticals’ new Helicobacter pylori drug, Leflunomide (TNP-2198), is experiencing a thrilling leap before commercialization – this world’s first differentiated antibiotic, which has advanced to the Phase III clinical endpoint, is regarded as the “hope of the whole village” by the company, but also carries the triple test of solving the drug resistance dilemma, overcoming medical insurance barriers, and increasing sales volume. As a potential solution for 44% of the infected population in China, the clinical value of levofloxacin and the 775 million yuan commercial betting agreement ignite capital imagination; But Dano Pharmaceuticals’ 530% debt ratio and cash flow crisis have made the market closely monitor every move in its August NDA submission ...
- Source: drugdu
- 40
- August 19, 2025
Asia Pharma Expo

Organiser: Nexzen Solutions Pvt. Ltd. Time：February 12 – February 14, 2026 address：Plot# 66, Block#C, Umme Kulsum Road, Bashundhara R/A, Dhaka-1229, Bangladesh Exhibition hall：International Convention City, Bashundhara Dhaka Product range: Pharmaceutical processing machinery (for tablets/capsules/liquids/injectables/ointments/dry syrups) Packaging machinery and equipment, packaging materials, API consumables, raw material drug additives, auxiliary materials, finished pharmaceutical products, and formulation laboratory reagents Glass products and equipment for analysis, R&D equipment, biotechnology instruments, and environmental control equipment Service utility products, one-stop service contractors, and project consulting services About Asia Pharma Expo： The Asia Pharma Expo in Dhaka, Bangladesh, is the most large-scale, influential, and the only internationally standardized pharmaceutical raw materials and equipment exhibition in Bangladesh. Strongly supported by the Bangladesh Pharmaceutical Industry Association, it serves as a vital platform for pharmaceutical information exchange in Bangladesh and its surrounding regions.
- Source: drugdu
- 40
- August 19, 2025
Doctors Seek Best Way to Treat Newly Discovered Genetic Disorder

By Carole Tanzer Miller HealthDay ReporterSATURDAY, Aug. 16, 2025 (HealthDay News) — Most folks probably think of gene mutations as something people are born with, but genes can also change later in life, sometimes making people sick. Scientists recently discovered a new disease that starts just that way in midlife. Called VEXAS, it’s marked by repeated attacks of inflammation caused by an immune system that goes rogue and attacks its own cells. “Part of normal aging is that all our cells develop mutations,” Dr. David Beck, a New York University geneticist who was part of the team that discovered VEXAS, told NIH News in Health. “It’s just normal wear and tear on our cells as we get older.” The type of mutation that causes VEXAS — known as an acquired mutation — is not passed on from parent to child. Acquired mutations develop, instead, over a lifetime, and exposure to ...
- Source: drugdu
- 42
- August 18, 2025
Amino acid metabolism shapes the tumor immune microenvironment and therapy response

The tumor microenvironment is not just a site of cancer growth—it is a high-stakes metabolic contest where tumor and immune cells vie for limited resources. Amino acids, once seen as passive nutrients, are now known to steer cell fate, immune suppression, and resistance to immunotherapy. Tumors often win this battle by monopolizing amino acids, crippling the metabolism of nearby T cells and macrophages. Recent advances have illuminated how this biochemical imbalance hinders immune surveillance and fosters tumor progression. Due to these challenges, there is a growing urgency to explore how amino acid dynamics influence cancer immunity and identify new therapeutic targets within this hidden battleground. In a new review (DOI: 10.20892/j.issn.2095-3941.2025.0115) published in Cancer Biology & Medicine, scientists from Tongji University Cancer Center explored how amino acid metabolism governs the intricate dialogue between cancer cells and immune defenses. The paper charts a comprehensive map of how amino acid sensing, transport, ...
- Source: drugdu
- 42
- August 18, 2025
The company is not involved in the vaccine business

Everyday AI Newsflash: An investor asked on the investor interaction platform: Has the company participated in the research and development of an AIDS vaccine? Does the company have this technology? Tiantan Biological (600161.SH) stated on the investor interaction platform on August 15 that the company is not involved in the vaccine business. The company’s main business is the research and development, production and sales of blood products, and it is in the blood products industry. At present, the company has launched three major categories of products, namely human albumin, human immunoglobulin and human coagulation factor, as well as recombinant coagulation factor products. https://finance.eastmoney.com/a/202508153485469676.html
- Source: drugdu
- 36
- August 18, 2025
Shingrix is superior to HZ/su vaccine in head-to-head comparison

On August 18th, Green Bamboo Biology-B (02480) announced that a head-to-head comparative study of its core product LZ901 and the recombinant glycoprotein E(gE) subunit vaccine HZ/su vaccine (Shingrix®) was conducted, and positive immunogenicity and safety data were obtained. This study recruited 301 healthy adults aged 50 and above. The results showed that LZ901 was superior to the HZ/su vaccine in both cellular immunogenicity and safety. In terms of specific immunogenicity results, LZ901 did not perform worse than the HZ/su vaccine in CD4+ and CD8+T cell immune responses. The proportion of gE specific CD4+T cell responders was 83.0%, while that of the HZ/su vaccine was 58.1%. The proportion of gE specific CD8+T cell responders was 46.8%, and that of HZ/su vaccine was 8.8%. In terms of safety, the adverse reaction rate of LZ901 was 41.1%, significantly lower than 87.9% of the HZ/su vaccine, and most of the reported reactions were mild ...
- Source: drugdu
- 36
- August 18, 2025
Soaring 1515%! The “champion of growth rate” among innovative drugs has made its debut

Amid the ever-changing capital market, the increase in the share price of Beihai Kangcheng is undoubtedly a remarkable and phenomenon-level event. Starting from a low of HK $0.13 at the beginning of this year, the share price of Cansino Biologics has been surging. As of the close of trading on August 13th, it has soared to HK $2.1, achieving an astonishing growth of over 15 times compared to the beginning of the year, with an increase of as high as 1,515%. This astonishing increase has become a hot topic of discussion in the capital market. In the current highly competitive pharmaceutical industry and with rapidly changing policy environments, why has the share price of Cansino Biologics been able to soar and become a favorite of the capital market? Good news keeps coming The share price of Beihai Kangcheng has soared, mainly due to the recent dual positive factors. On August ...
- Source: drugdu
- 33
- August 18, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.